



BETTER SLEEP, BETTER HEALTH  
and a BETTER LIFE

## ASX RELEASE

22 June 2017

### Cleansing Notice – Share purchase plan

Under ASIC Class Order 09/425 (**CO 09/425**), Oventus Medical Limited (ASX: OVN) (**Oventus**) gives notice that:

- (a) Oventus will make offers to issue ordinary shares under a share purchase plan (**SPP**) without disclosure under part 6D.2 *Corporations Act 2001* (Cth) (**Corporations Act**);
- (b) this notice is given under CO 09/425 and in particular, paragraph 7(f)(ii) of CO 09/425 which requires that Oventus gives this notice to ASX within the 24 hour period before the SPP offer;
- (c) at the date of this notice, Oventus has complied with:
  - (i) the provisions of chapter 2M *Corporations Act* as they apply to Oventus; and
  - (ii) section 674 *Corporations Act*; and
- (d) at the date of this notice, there is no 'excluded information' (within the meaning of sections 708A(7) and 708A(8) *Corporations Act*, as if this notice were a notice under section 708A(5)(e) *Corporations Act*).

For and on behalf of the board of Oventus.

Mel Bridges  
Chairman

**-ENDS-**

For more information please contact:

Dr Mel Bridges, Chairman: M: 0413 051 600 (+61 41 3051 600)

Kyahn Williamson, WE Buchan: P: 03 8866 1214 or [kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

**About Oventus**

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

A clinical study completed earlier this year showed the company's first generation product the O2Vent Mono™ is successful in treating OSA and that snoring was either eliminated or significantly reduced in 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.<sup>1</sup>

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP<sup>2</sup>. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.<sup>3</sup>

<sup>1</sup> *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

<sup>2</sup> *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

<sup>3</sup> *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*